HOME > Investors > Press Releases
Subject Korean Company, ViroMed Co., Ltd. Completes First Clinical Trial in the US
Writer ViroMed
Date 2008/10/27
MINNEAPOLIS, Minn. – (October 27, 2008) – The Korean Company, ViroMed Co., Ltd, recently completed enrollment for the first phase of its VM202 clinical trial, a gene-based therapy for treating critical limb ischemia, one of the severest types of peripheral artery disease, at the Minneapolis Heart Institute Foundation. It is the first clinical trial to be completed by the Korean-based company in the US .

The VM202 treatment for critical limb ischemia (CLI) is directed at restoration of blood flow to affected areas through regenerative angiogenesis. The term ˝angiogenesis˝ describes interventions that stimulate or induce new blood vessel growth.

"Therapeutic angiogenesis is a novel strategy for the treatment of cardiac and vascular diseases. The use of gene therapy products such as VM202 represents a potentially significant advance in this area of medicine," said Tim Henry, M.D., an interventional cardiologist and director of research at the Minneapolis Heart Institute Foundation.

Under Dr. Henry’s direction, ViroMed is studying the results of VM202 for the treatment of (CLI), which results from severe obstruction of arteries due to advanced peripheral artery disease PAD.

"We are very pleased to have completed enrollment for this clinical trial and look forward to the results," said Dr. Sunyoung Kim, president and chief executive officer. "VM202 may be able to reverse ischemic processes, reducing patient pain and incidence of ulceration."

PAD is one of the most common cardiovascular diseases. In patients with PAD, arteries that carry blood to the legs become narrowed or clogged and can cause muscle fatigue, cramping or pain. Over nine million Americans have PAD and it affects more than 20 percent of individuals over 70. PAD increases the risk of heart attack or stroke by four to five times and is the most common cause of leg amputation.

Minneapolis Heart Institute Foundation

The Minneapolis Heart Institute Foundation (MHIF) at Abbott Northwestern Hospital is creating a world without heart disease through groundbreaking clinical research and innovative educational programs. More information is at www.mplsheart.org.